Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Clinical role
Opportunistic quantitative CT measurement and clinician-review support across the labeled AI-CVD modules.
Keep in mind: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat Input: DICOM CT studies, including noncontrast thoracic CT, CAC studies, contrast CCTA or CTPA, and labeled abdomen or pelvis examinations.
Who uses it?Intended users: Trained physicians and qualified healthcare professionals who review quantitative CT measurements.
What does the software produce?Output: Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.
What is its most important limitation?Key limitation: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
Clinical takeaway. Clinical role: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation and retrospective clinical validation; prospective clinical studies were not required. AI-CVD measurements, including on MESA and FHS cohorts, were compared with manual expert measurements or gold standard reference tests. The coronary calcium module was evaluated against manually measured Agatston scores on 913 consecutive calcium screening CT scans from three community imaging centers; several other modules used agreement analyses, such as Bland–Altman, against manual measurements. No numeric agreement results are stated. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
The exact FDA document reports software verification and validation and retrospective clinical validation; prospective clinical studies were not required. AI-CVD measurements, including on MESA and FHS cohorts, were compared with manual expert measurements or gold standard reference tests. The coronary calcium module was evaluated against manually measured Agatston scores on 913 consecutive calcium screening CT scans from three community imaging centers; several other modules used agreement analyses, such as Bland–Altman, against manual measurements. No numeric agreement results are stated. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Prospective clinical studies were not required to demonstrate the safety and effectiveness of the device. Instead, clinical validation studies were performed based upon retrospective analyses". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation and retrospective clinical validation; prospective clinical studies were not required. AI-CVD measurements, including on MESA and FHS cohorts, were compared with manual expert measurements or gold standard reference tests. The coronary calcium module was evaluated against manually measured Agatston scores on 913 consecutive calcium screening CT scans from three community imaging centers; several other modules used agreement analyses, such as Bland–Altman, against manual measurements. No numeric agreement results are stated. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software Verification and Validation testing was completed to demonstrate the safety and effectiveness of the device." … "Prospective clinical studies were not required to demonstrate the safety and effectiveness of the device. Instead, clinical validation studies were performed based upon retrospective analyses". Read from the exact FDA decision document on 2026-11-14.
No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252029 FDA evidence package for AI-CVD
DesignFDA 510(k) verification and validation evidence described in the exact submission
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CT studies, including noncontrast thoracic CT, CAC studies, contrast CCTA or CTPA, and labeled abdomen or pelvis examinations.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM CT input and module outputs to the parent software are described in the FDA package; test local PACS/RIS routing, identifiers, result return, and failure handling.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes either a cloud-based AWS analysis server or an on-premises hospital server; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automated calcium, chamber, vascular, lung, liver, bone, muscle, and fat measurements with reference comparisons for human review and confirmation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes either a cloud-based AWS analysis server or an on-premises hospital server; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
DICOM CT input and module outputs to the parent software are described in the FDA package; test local PACS/RIS routing, identifiers, result return, and failure handling.
Only trained physicians and qualified healthcare professionals who review quantitative ct measurements. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K252029 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
The FDA package describes either a cloud-based AWS analysis server or an on-premises hospital server; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
exact submission · checked 2026-09-04
FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.
DICOM CT input and module outputs to the parent software are described in the FDA package; test local PACS/RIS routing, identifiers, result return, and failure handling.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price or product-specific reimbursement was established in the reviewed public material.
Monitor K252029 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: AI-CVD is not diagnostic interpretation or risk prediction. Except for the labeled CAC function, modules are not standalone; users must review and accept or reject results, and module-specific acquisition and body-region limits apply.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
11Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
Screened 11 PubMed titles and one trial record. Several titles use AI-CVD as a study label, but none states the tested AI-CVD software release or K252029; the trial is unrelated, so all 12 candidates are quarantined. The current discovery snapshot contains 11 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.
Authorized purpose: uOmnispace.CT is software for viewing, manipulating, evaluating, and analyzing medical images within healthcare institutions. The FDA indication lists colon visualization, dental panoramic and paraxial reconstruction, lung and airway segmentation and quantitative parameters, nodule analysis, vessel and brain-perfusion analysis, heart and coronary analysis, calcium scoring, dynamic analysis, bone-structure labeling, liver evaluation, dual-energy processing, and cardiovascular combined analysis.
Modality
CT/CTA
Anatomy
Colon, jaw, lungs, airways, brain, heart, vessels, liver, spine, ribs, and other labeled CT regions
Authorized purpose: uOmnispace.CT provides healthcare institutions with tools to view, manipulate, evaluate, and analyze medical CT images, including colon, lung, vessel, brain, cardiac, liver, rib, spine, dual-energy, perfusion, and cardiovascular applications described in the exact FDA submission.
Modality
CT/CTA
Anatomy
Colon, lungs and airway, vessels, brain, heart, liver, ribs, spine, and other CT regions
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.
Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.